The Impact of Intraoperative Methadone on Perioperative Opioid Requirements in Autologous Free Flap Breast Reconstruction
Journal of Reconstructive Microsurgery · 2026-11 · 42 (09) · 758-766
DOI: 10.1055/a-2717-5119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Reconstructive Microsurgery, online erschienen am 30.10.2025. Verfasst von Sydney Somers und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Utah School of Medicine, Salt Lake City, Utah, United States. Hauptthemen laut MEDLINE: Mammaplasty, Methadone, Analgesics, Opioid, Postoperative Pain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
The use of intraoperative methadone has received considerable attention due to reports of reduced postoperative pain and opioid consumption without increased risk of opioid-related side effects. The purpose of this study was to compare perioperative opioid requirements in patients who received intraoperative methadone to those who did not receive intraoperative methadone following autologous breast reconstruction (ABR). A retrospective review of patients who underwent ABR from July 2023 to August 2024 was performed. Patients were stratified into an intraoperative methadone and nonintraoperative methadone cohort. Patient demographics, operative characteristics, hospital length of stay, and perioperative opioid consumption per patient were collected. The primary outcome was daily postoperative opioid requirements, recorded in morphine milligram equivalents (MME). A total of 112 patients who underwent ABR breast reconstruction were identified, 54 in the intraoperative methadone cohort and 58 in the nonintraoperative methadone cohort. Mean opioid consumption was significantly less for the methadone cohort intraoperatively (23.7 ± 13.7 MME vs. 44.5 ± 18.8 MME, p < 0.01), on postoperative day (POD) 1 (29.04 ± 28.9 MME vs. 44.4 ± 37.9 MME, p = 0.04), POD-2 (22.9 ± 25.7 MME vs. 38.7 ± 38.2 MME, p = 0.04), and overall throughout hospitalization compared with the nonintraoperative methadone patients (87.4 ± 87.1 vs. 139.1 ± 121.2; p = 0.03). Intraoperative methadone significantly reduces inpatient opioid use after undergoing ABR on POD-1, POD2, and overall throughout hospitalization. Our findings support the need for well-designed prospective trials to further assess the effectiveness of intraoperative methadone in managing perioperative pain and reducing opioid use during ABR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Utah School of Medicine, Salt Lake City, Utah, United States.
ORCID-Profile: Sydney Somers
Zitieren
APA
Somers, S., Vitale, A., Dadzie, A., French, M., Eddington, D., Agarwal, J. P., & Kwok, A. C. (2026). The Impact of Intraoperative Methadone on Perioperative Opioid Requirements in Autologous Free Flap Breast Reconstruction. Journal of Reconstructive Microsurgery, 42(09), 758-766. https://doi.org/10.1055/a-2717-5119
Vancouver
Somers S, Vitale A, Dadzie A, French M, Eddington D, Agarwal JP, et al. The Impact of Intraoperative Methadone on Perioperative Opioid Requirements in Autologous Free Flap Breast Reconstruction. Journal of Reconstructive Microsurgery. 2026;42(09):758-766. doi:10.1055/a-2717-5119
BibTeX
@article{Somers2026,
author = {Somers, Sydney and Vitale, Alexandra and Dadzie, Aaron and French, Mackenzie and Eddington, Devin and Agarwal, Jayant P and Kwok, Alvin C},
title = {The Impact of Intraoperative Methadone on Perioperative Opioid Requirements in Autologous Free Flap Breast Reconstruction},
journal = {Journal of Reconstructive Microsurgery},
year = {2026},
volume = {42},
number = {09},
pages = {758--766},
doi = {10.1055/a-2717-5119}
}
EUVIMED